title: Predictive value of increased plasma levels of fibronectin in gestational hypertension.
abstract: Blood pressure, proteinuria, and plasma fibronectin and plasminogen activator inhibitor-1 levels were measured in 120 apparently healthy normotensive primigravid women during the first, second, and third trimesters of pregnancy and 2 days post partum. Thirty-two women developed hypertension (diastolic blood pressure greater than or equal to 90 mm Hg) that in 17 women was associated with proteinuria (greater than 0.3 gm/day). Fibronectin levels were 83% +/- 22% of normal (mean +/- SD) during the first trimester and 75% +/- 20% at term in the healthy women but increased from 94% +/- 36% to 187% +/- 36% in the women who developed gestational hypertension (with or without proteinuria) (p less than 0.0001). Plasminogen activator inhibitor-1 levels increased from 26 +/- 19 ng/ml to 110 +/- 86 ng/ml in healthy women and from 32 +/- 35 ng/ml to 290 +/- 90 ng/ml in hypertensive women (p less than 0.001). Increased levels of fibronectin at 25 to 36 weeks of pregnancy (greater than or equal to mean + 2 SD of the healthy women, or greater than 140%) were found in 31 of the 32 women with gestational hypertension with or without proteinuria and in 5 of the 88 healthy women (sensitivity 96%, specificity 94%). Fibronectin levels increased 3.6 +/- 1.9 weeks earlier than the onset of hypertension and/or proteinuria. Increased levels of plasminogen activator inhibitor-1 at 25 to 32 weeks (greater than or equal to 280 ng/ml) were found in 16 of the 32 women who developed gestational hypertension with or without proteinuria and in 4 of the 88 healthy women (sensitivity 50%, specificity 95%). We conclude that increased fibronectin levels are the best predictor of gestational hypertension with or without proteinuria and that its level in plasma increases several weeks before the development of hypertension.
authors.affiliation: Center for Thrombosis and Vascular Research, University of Leuven, Campus Gasthuisberg, Belgium.
authors.forename: V
authors.initials: V
authors.lastname: Ballegeer
authors.forename: B
authors.initials: B
authors.lastname: Spitz
authors.forename: L
authors.initials: L
authors.lastname: Kieckens
authors.forename: H
authors.initials: H
authors.lastname: Moreau
authors.forename: A
authors.initials: A
authors.lastname: Van Assche
authors.forename: D
authors.initials: D
authors.lastname: Collen
mesh_terms: D005260:Female; D005353:Fibronectins / Q000097:blood*; D006023:Glycoproteins / Q000097:blood; D006801:Humans; D006973:Hypertension / Q000097:blood*; D010960:Plasminogen Activators / Q000037:antagonists & inhibitors; D015849:Plasminogen Inactivators; D049590:Postpartum Period / Q000097:blood; D011225:Pre-Eclampsia / Q000097:blood*; D011247:Pregnancy; D011379:Prognosis; D011446:Prospective Studies; D011507:Proteinuria / Q000097:blood
chemical_list: D005353:Fibronectins; D006023:Glycoproteins; D015849:Plasminogen Inactivators; D010960:Plasminogen Activators